The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2015

Filed:

Apr. 01, 2010
Applicants:

Zhi Liu, Jamestown, NC (US);

Saujanya L. Gosangari, Greensboro, NC (US);

Dana S. Toops, Parkland, FL (US);

Aqeel Fatmi, Greensboro, NC (US);

Inventors:

Zhi Liu, Jamestown, NC (US);

Saujanya L. Gosangari, Greensboro, NC (US);

Dana S. Toops, Parkland, FL (US);

Aqeel Fatmi, Greensboro, NC (US);

Assignee:

Banner Life Sciences LLC, High Point, NC (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61P 5/34 (2006.01); A61K 9/48 (2006.01); A61K 31/57 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2006.01);
U.S. Cl.
CPC ...
A61K 9/4858 (2013.01); A61K 31/57 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01);
Abstract

Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.


Find Patent Forward Citations

Loading…